Serotonergic sensitivity in borderline personality disorder: preliminary findings.
Twelve patients with borderline personality disorder and 15 healthy comparison subjects were challenged with single doses of oral m-chlorophenylpiperazine (m-CPP) and placebo. Following m-CPP, the patients experienced decreased anger and fear. Seven of the 12 patients reported a "spacy," "high," depersonalized/derealized experience following m-CPP, which was confirmed by clinicians' ratings. Compared with the normal male subjects, the male patients with borderline personality disorder had higher cortisol levels and marginally blunted prolactin responses after receiving m-CPP. These results suggest serotonergic dysfunction in borderline personality disorder.
Hollander
E
E
Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York.
Stein
D J
DJ
DeCaria
C M
CM
Cohen
L
L
Saoud
J B
JB
Skodol
A E
AE
Kellman
D
D
Rosnick
L
L
Oldham
J M
JM
D000284:Administration, Oral; D000328:Adult; D000786:Anger / Q000187:drug effects; D001883:Borderline Personality Disorder / Q000175:diagnosis* / Q000503:physiopathology; D003861:Depersonalization / Q000139:chemically induced; D005239:Fear / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology; D010919:Placebos; D011388:Prolactin / Q000097:blood; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D012701:Serotonin / Q000502:physiology*
D010879:Piperazines; D010919:Placebos; D011985:Receptors, Serotonin; D012701:Serotonin; D011388:Prolactin; C015068:1-(3-chlorophenyl)piperazine